Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
STTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.69 - $3.95
Previous CloseN/A
Volume43.14K
Average Volume (3M)371.55K
Market Cap
$36.48M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.87
Next Earnings
Aug 07, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding47,903,214
10 Day Avg. Volume162,100
30 Day Avg. Volume371,546
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.00Price Target Upside426.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe company's pivot into inflammatory bowel disease (IBD) is seen as an underappreciated opportunity, with the lead program SL-325 representing a first-in-class approach with the potential to improve upon related, clinically-validated, TL1A targeting programs.
Financial PerformanceThe announcement of 1Q25 results showed an EPS of ($0.27), which was better than both the analyst's estimate of ($0.40) and the consensus of ($0.28).
Preclinical DataPreclinical results demonstrated SL-325 safety and feasibility of maintenance dosing, with a lead DR3 bispecific candidate nomination expected later this year.
Bears Say
Early Stage PipelineThe early stage of the company pipeline and a lack of near-term value drivers lead to maintaining a Hold Rating for Shattuck.
Operational FundingManagement expects the company's $60.9 million to fund operations into 2027, beyond results from its Phase 1 clinical trial of SL-325.
Research And Development CostsShattuck released its Q1 financials, including R&D expenses of $9.9MM and SG&A expenses of $4.5MM, leading to Q1 net losses of $13.7MM.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $0.69 and its highest was $3.95 in the past 12 months.
What is Shattuck Labs’s market cap?
Shattuck Labs’s market cap is $36.48M.
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Aug 07, 2025 which is in 5 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on May 01, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.281 by $0.011.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -0.25.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 47,903,214 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.281. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
Shattuck Labs Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (426.32% Upside)
$4.00 (426.32% Upside)
Blogger Sentiment
Neutral
STTK Sentiment 50%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.6%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.87%
12-Months-Change
Fundamentals
Return on Equity
-71.90%
Trailing 12-Months
Asset Growth
-47.27%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$4.00
▲(426.32%Upside)
Technical Analysis
PolyPid
―
Coeptis Therapeutics Holdings
―
LAVA Therapeutics
―
Xilio Therapeutics
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
19.04% Insiders
7.03% Mutual Funds
0.10% Other Institutional Investors
69.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---